Table 5 The clinical characteristics and chemotherapy response of high-risk postmolar GTN
Variables* | Control (n = 9) | P-chem (n = 3) | P value |
|---|---|---|---|
Interval from HM to GTN (days) | 62 (27–1095) | 87 (54–2920) | 0.309 |
Largest dimension of tumor(cm) | 5.0 (1.1–9.5) | 5.5 (3.2–9.7) | 0.459 |
Number of metastases | 2 (0–11) | 1 (0–5) | 0.509 |
hCG before first-line chemotherapy(IU/L) | 92,561 (11,235–1,000,000) | 22,913 (17,625–126,575) | 0.405 |
FIGO stagea | |||
I | 0 (0%) | 1 (33%) | |
II | 1 (11%) | 0 (0%) | |
III | 6 (67%) | 2 (67%) | |
IV | 2 (22%) | 0 (0%) | |
WHO risk score | 7 (7–14) | 9 (7–10) | 0.426 |
Resistant to first-line drug | 1 (11%) | 0/3 (0%) | 1.000 |
Chemotherapy cycles to hCG normalization | 4 (3–8) | 4 (4–4) | 0.352 |
Total chemotherapy cycles | 8 (6–9) | 7 (7–10) | 0.924 |